May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 1 Year
Author Affiliations & Notes
  • E. Sellem
    Lyon, France
  • J. Rouland
    Ophthalmology, Regional University Hospital, Lille, France
  • E. Piriou
    CLP Santé, Paris, France
  • C. Le Pen
    Health Economics, Université Paris Dauphine, Paris, France
  • Glaucoma Study Group
    Health Economics, Université Paris Dauphine, Paris, France
  • Footnotes
    Commercial Relationships  E. Sellem, Pharmacia C; J. Rouland, Pharmacia C; E. Piriou, Phaemacia C; C. Le Pen, Pharmacia C.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 174. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Sellem, J. Rouland, E. Piriou, C. Le Pen, Glaucoma Study Group; Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 1 Year . Invest. Ophthalmol. Vis. Sci. 2003;44(13):174.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To prospectively observe second-line treatment strategies, their clinical outcomes, and treatment costs in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in France. Methods: 500 patients were recruited between 1998 and 2000 in 37 centers and were followed for up to two years. Outcomes were numbers of and reasons for treatment changes, changes in clinical parameters (intraocular pressure [IOP] levels, visual field defects, and optic nerve excavation), and direct medical costs associated with glaucoma management in patients receiving monotherapy or combination therapy. This work reports results of an interim analysis of one-year follow-up data for patients having at least two contacts with a study ophthalmologist. Results: Data were analyzed for 410 patients and 799 treated eyes. Ocular hypotensive monotherapy was used as first-line therapy in 93.0% of eyes. Second-line treatment was initiated an average of 2.8 ± 0.3 years after diagnosis, primarily due to insufficient IOP control (61.7%). Mean IOP reductions after one year of second-line therapy were 3.5 mmHg in eyes treated with latanoprost monotherapy versus 1.9 mmHg in those receiving beta-blocker monotherapy (p<0.001) and 4.6 mmHg in eyes treated with the latanoprost + timolol combination versus 3.0 mmHg in those receiving combination therapies that did not include latanoprost (p=0.011). The annual cost of treatment was 262 euros per eye. The average daily cost for latanoprost monotherapy (0.65 euro/day) was similar to that for patients who failed beta-blocker monotherapy (0.68 euro/day, p=0.26); latanoprost + timolol was less costly (0.88 euro/day) than therapeutic combinations without latanoprost (0.98 euro/day, p=0.014). Conclusion: Insufficient IOP control is the main reason for changing first-line treatment in patients with POAG or OH. After one year, second-line treatment with latanoprost, as monotherapy or combined with timolol, provides superior IOP control at an acceptable cost.

Keywords: clinical (human) or epidemiologic studies: hea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.